
# **Executive Summary**

We analysed the sales and marketing data of the pharmaceutical company, generating 411,655 units of drug sales over the period of January 2012 to July 2013. The analysis focused on evaluating the impact of different marketing strategies in driving sales performance and understanding their correlation with sales trends



4 main different trends during analyzed period:

- 1 Q1/12 to Q3/12 Slow constant decline
- 2 Q4/12 Slow recover with deep falls in some weeks of Nov and Dec
- **3 Q1/13 Accelerated growth** until mid March/13
- 4 Q2/13 to Q3/13 Steepen drop in volume

# **Key Insights and Recommendations:**

- Sales performance not cyclical, although not much historical data to conclude.
- Identifying correlation and causality from activities is difficult due to so many activities happening at the same time (unless applying A/B Testing)
- Should **focus efforts on Sales Rep Details** and **Sampling** effectiveness (increase productivity) that **seem to correlate** more with sales performance
- **Speaker programs** should be **carefully picked and executed** to guarantee impact
- **Loyalty cards** should be **minimized** to specific objectives (e.g. promoting volume for low-income patients) but **not extended.** Budget can be reallocated to Details and sampling

# Marketing Strategy Assessment Sales Rep Details

- Good correlation, increase in activity show benefit in sales volume as result (from Q1 to Q3 2012)
- The activity has become **part of the baseline**, i.e. removing these will **strongly impact sales volume**. In high competitive environment can **secure strong relationships** with physicians and **defend volume share**
- Evaluate and optimize efficacy of activity based on KPIs at granular level. \* See attached Data analysis & KPI sheet\*

# Sales by Week



# Sales by Region

, massiy secire raining												
	Geography	1	2	3	4	5	6	7	8	9	10	Grand
	na	2										2
	PR00 - PUERTO RIC				124						515	639
	RT01 - NORTHEAST	180	4,120	11,783	17,004	18,431	18,312	14,623	14,821	12,287	5,215	116,775
	RT02 - SOUTH	209	2,015	6,586	10,125	12,610	10,459	11,958	11,485	7,398	11,113	83,957
	RT03 - WEST	134	2,286	7,840	9,053	9,253	11,907	11,030	6,707	9,739	7,719	75,667
	RT04 - CENTRAL	109	1,634	5,342	8,376	10,231	11,343	9,509	7,979	6,190	4,361	65,074
	RT05 - GREAT LAK	127	2,148	7,217	9,668	11,436	10,812	11,225	6,178	7,542	3,188	69,541
	Grand Total	761	12,203	38,768	54,350	61,961	62,834	58,344	47,169	43,155	32,111	411,655

# Higher industry ranking provides greater productivity per detail (invested)

#### # Details by Week




#### Sales Volume per Detail

y	Industry Decile Ranking											
	Geography	1	2	3	4	5	6	7	8	9	10	Gran
	na	0.40										0.10
	PR00 - PUERTO RICO				3.66						12.87	8.64
	RT01 - NORTHEAST	0.56	1.44	1.74	2.05	2.41	2.94	3.39	4.16	5.08	8.53	2.71
d	RT02 - SOUTH	0.78	1.43	1.57	1.69	2.31	2.67	3.27	4.69	5.07	7.77	2.78
	RT03 - WEST	0.97	1.09	1.61	1.66	1.87	2.48	2.74	3.97	4.88	10.17	2.46
	RT04 - CENTRAL	0.99	1.85	1.83	2.07	2.22	2.97	3.26	3.90	4.89	7.34	2.80
	RT05 - GREAT LAKES	0.93	1.54	1.66	1.82	2.33	2.52	3.23	3.40	6.62	6.20	2.54
	Grand Total	0.78	1.41	1.68	1.87	2.25	2.72	3.17	4.08	5.21	8.13	2.66

- 1 KPI: How much sales can be made per detail (invested)
- 2 Set benchmarks in same industry decile and use for goal setting on all zones
- 3 Copy good practices from zones that have better KPI performance
- 4 Re-allocate budget from less effective zones to other ones

# Marketing Strategy Assessment Free Samples


- Good correlation, with sales as well as details (likely due to sample distribution during sales representative visits)
- The activity has also become **part of the baseline**, i.e. removing these will **strongly impact sales volume**. However, for a **product launched 3 years ago**, evaluation of **high ratio -1.3 units of sample per unit sold-** needs to be assessed (if sustainable)
- Evaluate and optimize efficacy of activity based on KPIs at granular level



- 1 Productivity KPIs are required to optimize investment
- 2 How many **samples** are been given away per unit sold
- 3 Set benchmarks in same industry decile and use for goal setting on all zones
- 4 Perform surveys at patient level per zone to identify if samples are consumed (or simply kept at the physician)

# **Marketing Strategy Assessment Loyalty Cards**

- Strong increase of loyalty cards from Q4 2012 going forward, with no correlation with sales volume performance
- High concentration of loyalty card in industry deciles 5,6,7 and 8 across all zones, Northeast been a high promotor



## Sales by Region

_				y Declie R	alikiliy										
ly	Geography	1	2	3	4	5	6	7	8	9	10	Grand			
	na	2										2			
	PR00 - PUERTO RIC				124						515	639			
	RT01 - NORTHEAST	180	4,120	11,783	17,004	18,431	18,312	14,623	14,821	12,287	5,215	116,775			
	RT02 - SOUTH	209	2,015	6,586	10,125	12,610	10,459	11,958	11,485	7,398	11,113	83,957			
	RT03 - WEST	134	2,286	7,840	9,053	9,253	11,907	11,030	6,707	9,739	7,719	75,667			
	RT04 - CENTRAL	109	1,634	5,342	8,376	10,231	11,343	9,509	7,979	6,190	4,361	65,074			
	RT05 - GREAT LAK	127	2,148	7,217	9,668	11,436	10,812	11,225	6,178	7,542	3,188	69,541			
d	Grand Total	761	12,203	38,768	54,350	61,961	62,834	58,344	47,169	43,155	32,111	411,655			

# # Loyalty Cards by Region

			2012											2013 Q1 Q2 (						Q3	1
		Jan	Q1 Feb	March	April	Q2 May	June	July	Q3 Augu.	Sep	Oct	Q4 Nove.	Dec	Jan		March	April		June		
	250									Ċ									. 1		G
	230																		ы	Ш	n P
	200															na.			ĻI	Ш	R
#Loyalty Cards	150														da			1			R
#Loy	100													d		1					R
	50				_===	dell	alla.		8	. III	4								1 n	ull	G
		27	24	9 23	27	25	8 22	27	10 24	28	26	9 23	28	25	8 22	8 22	26	10 24	28	26	


# Loyalty Cards

-	Industry Decile Ranking											
Geography	1	2	3	4	5	6	7	8	9	10	Grand	
na												
PR00 - PUERTO RIC												
RT01 - NORTHEAST		46	254	176	294	190	288	377	142	98	1,865	
RT02 - SOUTH	1	16	59	157	308	179	338	391	133	187	1,769	
RT03 - WEST	8	33	33	86	151	111	71	22	99	221	835	
RT04 - CENTRAL		8	75	139	156	247	158	397	74	90	1,344	
RT05 - GREAT LAK	10	8	42	112	231	300	331	146	253	75	1,508	
Grand Total	19	111	463	670	1,140	1,027	1,186	1,333	701	671	7,321	

- Considering low correlation, a drastically reduction of this activity (limited to only selected low-income patients) is required
- Re-allocation of budget to Details and Sampling can more effectively sales growth.

# Marketing Strategy Assessment Speaker Programs

- Apparent strong correlation between speaker events held during March 2013 and volume sold, but not quite the same for the
  rest of the period evaluated.
- Identified Promotional Lift from such event that benefited sales as a one off, after which decrease of volume was noticeable
- Don't provide sustainable volume lifts, so it needs to be also supported by strong Sales Rep Details (to guarantee
  engagement with physicians and continuity of speaker topics to back further prescriptions)



### Speaker Events



### Speaker Events by Region

Industry Decile Ranking											
Geography	1	2	3	4	5	6	7	8	9	10	Grand
na											2
PROO - PUERTO RIC											
RT01 - NORTHEAST	2	60	87	110	63	54	34	27	35	8	480
RT02 - SOUTH	1	6	23	20	19	18	20	14	2	4	127
RT03 - WEST	6	29	38	55	43	44	30	16	10	10	281
RT04 - CENTRAL	6	7	37	26	27	39	24	19	14	4	203
RT05 - GREAT LAK	7	16	53	30	50	30	36	15	9	1	247
Grand Total	22	118	238	241	202	185	144	91	70	27	1,340

- 1 Target and execute welldesigned events optimizing
  budget, even re-allocating
  budget from other less relevant
  events during the year
- To improve chance of successfully impacting volume, support event decisions on surveys oriented to physicians (understand drivers, and insights)

# **Medical Conference Assessment**

Focus on high-impact conferences and prioritize targeting physicians treating conditions aligned with the drug's strengths.


## Framework for Assessment

# **Objectives and Preparation**

- Lead Generation:# of physicians engaged.
- **Brand Awareness:** Increased knowledge about the drug.
- Prescription Impact:
   Changes in prescription
   behavior post-conference.
- Preparedness: Reinforce effectiveness supporting data of the drug (pre-Details before event)

# Data Collection during the Conference

- •# Interactions Tracked:
  # and quality of engagements
  with physicians.
- Follow-up Commitments:
  # physicians interested in follow-up meetings.



# **Post-conference monitoring**

- Prescription Lift:
   Increase in prescriptions
   from attendees.
- Sales Impact:

  Monitor sales growth from physicians who interacted at the booth.



# **Key Metrics**

- Lead Conversion Rate:
  % of engaged physicians who prescribe the drug.
- **ROI:** Conference investment costs Vs. revenue lift identified after event
- Payback: Of investments costs, if impact not associated to long-term benefits
- Cost per Lead: Measure costefficiency of interactions.